BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 18663759)

  • 1. A study on confidence intervals for incremental cost-effectiveness ratios.
    Wang H; Zhao H
    Biom J; 2008 Aug; 50(4):505-14. PubMed ID: 18663759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating incremental cost-effectiveness ratios and their confidence intervals with differentially censored data.
    Wang H; Zhao H
    Biometrics; 2006 Jun; 62(2):570-5. PubMed ID: 16918922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonparametric statistical methods for cost-effectiveness analyses.
    Dinh P; Zhou XH
    Biometrics; 2006 Jun; 62(2):576-88. PubMed ID: 16918923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uncertainty of incremental cost-effectiveness ratios. A comparison of Fieller and bootstrap confidence intervals.
    Severens JL; De Boo TM; Konst EM
    Int J Technol Assess Health Care; 1999; 15(3):608-14. PubMed ID: 10874387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem.
    Willan AR; O'Brien BJ
    Health Econ; 1996; 5(4):297-305. PubMed ID: 8880166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian estimation of cost-effectiveness from censored data.
    Heitjan DF; Kim CY; Li H
    Stat Med; 2004 Apr; 23(8):1297-309. PubMed ID: 15083484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial.
    Chaudhary MA; Stearns SC
    Stat Med; 1996 Jul; 15(13):1447-58. PubMed ID: 8841654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parametric modelling of cost data in medical studies.
    Nixon RM; Thompson SG
    Stat Med; 2004 Apr; 23(8):1311-31. PubMed ID: 15083485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incremental net benefit in randomized clinical trials.
    Willan AR; Lin DY
    Stat Med; 2001 Jun; 20(11):1563-74. PubMed ID: 11391688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness inferences from bootstrap quadrant confidence levels: three degrees of dominance.
    Obenchain RL; Robinson RL; Swindle RW
    J Biopharm Stat; 2005; 15(3):419-36. PubMed ID: 15920889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empirical estimation of life expectancy from large clinical trials: use of left-truncated, right-censored survival analysis methodology.
    Nelson CL; Sun JL; Tsiatis AA; Mark DB
    Stat Med; 2008 Nov; 27(26):5525-55. PubMed ID: 18613251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-parametric methods for cost-effectiveness analysis: the central limit theorem and the bootstrap compared.
    Nixon RM; Wonderling D; Grieve RD
    Health Econ; 2010 Mar; 19(3):316-33. PubMed ID: 19378353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and analysis issues for economic analysis alongside clinical trials.
    Marshall DA; Hux M
    Med Care; 2009 Jul; 47(7 Suppl 1):S14-20. PubMed ID: 19536012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Average cost-effectiveness ratio with censored data.
    Bang H; Zhao H
    J Biopharm Stat; 2012; 22(2):401-15. PubMed ID: 22251182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the equivalence of some medical cost estimators with censored data.
    Zhao H; Bang H; Wang H; Pfeifer PE
    Stat Med; 2007 Oct; 26(24):4520-30. PubMed ID: 17380543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Under-smoothed kernel confidence intervals for the hazard ratio based on censored data.
    Tu D
    Biom J; 2007 Jun; 49(3):474-83. PubMed ID: 17623350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An opportunity cost approach to sample size calculation in cost-effectiveness analysis.
    Gafni A; Walter SD; Birch S; Sendi P
    Health Econ; 2008 Jan; 17(1):99-107. PubMed ID: 17497751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-parametric bootstrap confidence intervals for the intraclass correlation coefficient.
    Ukoumunne OC; Davison AC; Gulliford MC; Chinn S
    Stat Med; 2003 Dec; 22(24):3805-21. PubMed ID: 14673940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A two-part model for censored medical cost data.
    Tian L; Huang J
    Stat Med; 2007 Oct; 26(23):4273-92. PubMed ID: 17330248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incremental cost-effectiveness ratios (ICERs): the silence of the lambda.
    Gafni A; Birch S
    Soc Sci Med; 2006 May; 62(9):2091-100. PubMed ID: 16325975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.